KineMed, Inc. Announces Presentations at The American Diabetes Association’s Annual Scientific Conference in San Diego, California
EMERYVILLE, Calif., June 9 /PRNewswire/ — KineMed, Inc., a platform-based drug development and advanced medical diagnostics company, announced today that it will make presentations related to two new product programs at the American Diabetes Association’s 65th Annual Scientific Sessions to be held in San Diego on June 10-14. KineMed will present its KineMarker(TM) assays for measuring insulin resistance and the adequacy of pancreatic beta-cell compensation (Poster # 616-P Category: Clinical Therapeutics/New Technology- Treatment of Insulin Resistance) and pancreatic beta-cell proliferation (Poster # 1658-P Category: Islet Biology). For information on the conference, please see http://scientificsessions.diabetes.org.
KineMed’s proprietary in vivo KineMarker(TM) assays provide new, sensitive and high-throughput measures of several key metabolic pathways involved in the pathogenesis and treatment of diabetes and other metabolic disorders. These assays can be used in clinical as well as pre-clinical settings. KineMed’s insulin resistance KineMarker(TM) is much easier to apply and less labor- intensive than the traditional hyperinsulinemic-euglycemic glucose clamp method, which is the current “gold-standard” in the field. Clinical trial efficiency and patient comfort are thereby improved considerably. Subjects drink a specially labeled glucose-containing drink, and a small amount of blood (i.e., a few drops) is taken after 2-3 hours have passed. At the American Diabetes Association meeting, KineMed will present results of a new study comparing the KineMarker(TM) test with the clamp method in lean individuals and obese subjects with Metabolic Syndrome. KineMed will also present data generated using the KineMarker(TM) assay in pre-clinical models of insulin resistance, including measurement of insulin-sensitizing drug effects, in both genetic and dietary models.
KineMed will also present recent results using the Company’s KineMarker(TM) assay to measure failure of pancreatic beta-cell compensation, the second key dimension in the pathogenesis of type 2 diabetes mellitus. Insulin resistance progresses to type 2 diabetes when failure of pancreatic beta-cell compensation occurs (termed “pancreatic exhaustion”). To date, there have been no methods for detecting early signs of pancreatic exhaustion.
Additionally, KineMed has developed and will present data describing a second product, a pre-clinical measure of pancreatic beta-cell proliferation. This assay provides a new, less labor-intensive, more sensitive and much more highly reproducible measure of insulin-secreting cell (pancreatic beta-cell) regeneration. New drug candidates that target the regeneration of pancreatic beta-cells are being developed, but previous methods could only measure pancreatic beta-cell mass by histology rather than the true regeneration rate of beta-cells, as KineMed’s test achieves. Data in several animal models of stimulated beta-cell proliferation will be presented.
David Fineman, President and CEO of KineMed, commented “We are excited about offering this technology to drug developers as it can be applied in vivo to screen for compounds that improve several key therapeutic targets, including insulin sensitivity, pancreatic beta-cell compensation to insulin resistance, and pancreatic beta-cell regeneration. We are particularly excited about clinical applications of the insulin resistance test to support development of new drugs targeting pre-diabetes, diabetes and the metabolic syndrome.”
About KineMed, Inc.
KineMed, Inc. provides a proprietary set of tools for measuring the dynamics of molecular and cellular response to drugs in the intact organism, both in animals and humans. KineMed’s technology is ideally suited to enable the discovery of entirely new, unanticipated uses for compounds (an approach called repurposing or repositioning) by screening for activity in vivo across a wide variety of disease states. The breadth of therapeutic targets covered by KineMarker(TM) assays allows high-throughput screening in conditions beyond those typically evaluated. KineMed’s technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of inflammation and neurodegeneration. For further information about KineMed, please visit: http://www.kinemed.com/.
